| Serial Number | 97180459 |
| Word Mark | MOLECURE |
| Filing Date | Monday, December 20, 2021 |
| Status | 807 - SU - NON-FINAL ACTION - MAILED |
| Status Date | Wednesday, January 24, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, May 23, 2023 |
| Description of Mark | The mark consists of the word "MOLECURE" in stylized font. |
| Goods and Services | Pharmaceutical, medical and veterinary preparations and substances, namely, pharmaceutical preparations and substances for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemico-pharmaceutical preparations for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; biochemical preparations for medical use, namely, biochemical preparations for the treatment of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer |
| Pseudo Mark | MOLE CURE |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Medical and pharmacological research services; research and development services in the field of antibodies; research and development services in the field of immunology; research and development in the pharmaceutical and biotechnology fields; drug discovery services; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; biological research, clinical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer, and medical research; medical laboratory services; scientific laboratory services; analysis of human tissues for medical research; laboratory services, namely, laboratory research services, medical laboratory services, scientific laboratory services relating to the production of monoclonal antibodies; medical research and scientific analysis in the field of immunology and antibodies; scientific research for medical purposes in the area of cancerous diseases; biomedical research services; biological research; research relating to biotechnology; clinical research and medical research in the field of inflammatory diseases and diseases leading to tissue fibrosis, immunology and cancer; chemical research and analysis services including analytical services relating to medicines, pharmaceutical preparations and biochemistry; research laboratories, namely, laboratory research in the field of chemistry; scientific and biotechnology research in the field of gene therapy; DNA screening for scientific research purposes; biological research, namely, cell separation research services; research and development services in the field of immunohistology; scientific research in the field of genetics and genetic engineering; consultancy relating to research and development in the field of therapeutics; product custom design and development of medical technology; services for the development of methods of testing, namely, development and establishment of testing specifications and procedures in the field of biotechnology and pharmaceutical fields; conducting technical project studies, namely, technical research in the field of pharmaceutical studies; preparation of project analysis studies, namely, conducting scientific study in the fields of medicine and biotechnology; technical consultancy relating to product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory services relating to scientific research; providing information about the results of clinical trials for others for pharmaceutical products |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 27, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | Thursday, November 30, 2017 |
| First Use In Commerce Date | Monday, November 30, 2020 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 20, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Thursday, November 30, 2017 |
| First Use In Commerce Date | Monday, November 30, 2020 |
| Party Name | MOLECURE SPÓLKA AKCYJNA |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | WARSZAWA POLAND 02-089 PL |
| Party Name | MOLECURE SPÓLKA AKCYJNA |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 03 - Corporation |
| Address | WARSZAWA POLAND 02-089 PL |
| Party Name | OncoArendi Therapeutics S.A. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Warszawa 02-089 PL |
| Event Date | Event Description |
| Wednesday, January 24, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, January 24, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 24, 2024 | SU - NON-FINAL ACTION - WRITTEN |
| Wednesday, January 24, 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| Thursday, January 4, 2024 | USE AMENDMENT FILED |
| Tuesday, January 23, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Thursday, January 4, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Tuesday, July 18, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, May 23, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 23, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, May 3, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, April 20, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, April 20, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, April 20, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, April 20, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, April 20, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, March 28, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, March 27, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, March 27, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, October 14, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, October 14, 2022 | NON-FINAL ACTION E-MAILED |
| Friday, October 14, 2022 | NON-FINAL ACTION WRITTEN |
| Sunday, September 25, 2022 | ASSIGNED TO EXAMINER |
| Wednesday, September 7, 2022 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Monday, December 27, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, December 23, 2021 | NEW APPLICATION ENTERED |